Amgen is trading 3.2% up at $397.61 in pre-market action ahead of its second-quarter 2026 earnings report scheduled for August 04.
- The move reflects investor positioning for the upcoming results and updates on key pipeline assets.
- Analysts have highlighted the obesity drug candidate MariTide as a primary focus in recent Q2 2026 earnings preview coverage.